High-Dose Administration of iPS Cell-Derived Cardiomyocyte Spheroids Shows Efficacy in Clinical Trial

WEB_06Gen1 iPS
High doses of cardiomyocyte spheroids derived from induced pluripotent stem (iPS) cells are effective in treating severe heart failure, according to interim results of a clinical trial.

New contents